Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

[1]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[2]  M. Tainsky,et al.  The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  Huan Yang,et al.  Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. , 2005, Current opinion in investigational drugs.

[4]  Alcino J. Silva,et al.  The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.

[5]  G. Fritz.  HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). , 2005, International journal of oncology.

[6]  R. Deschenes,et al.  DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras* , 2005, Journal of Biological Chemistry.

[7]  J. Schellens,et al.  Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.

[8]  W. Grizzle,et al.  Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors , 2005, Oncogene.

[9]  J. Hancock,et al.  Individual Palmitoyl Residues Serve Distinct Roles in H-Ras Trafficking, Microlocalization, and Signaling , 2005, Molecular and Cellular Biology.

[10]  C. Johannessen,et al.  The NF1 tumor suppressor critically regulates TSC2 and mTOR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Kluwe,et al.  Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. , 2005, Anticancer research.

[12]  M. Marra,et al.  Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. , 2005, Current drug targets.

[13]  S. Sebti.  Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. , 2005, Cancer cell.

[14]  D. Gutmann,et al.  Neurofibromatosis 1: from lab bench to clinic. , 2005, Pediatric neurology.

[15]  R. Lothe,et al.  Expression Patterns of Cell Cycle Components in Sporadic and Neurofibromatosis Type 1-Related Malignant Peripheral Nerve Sheath Tumors , 2005, Journal of neuropathology and experimental neurology.

[16]  S. Carroll,et al.  Tumor Suppressor Mutations and Growth Factor Signaling in the Pathogenesis of NF1-Associated Peripheral Nerve Sheath Tumors: II. The Role of Dysregulated Growth Factor Signaling , 2005, Journal of neuropathology and experimental neurology.

[17]  J. Declue,et al.  Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. , 2005, Cancer cell.

[18]  N. Hynes,et al.  Amplification and differential expression of members of theerbB-gene family in human glioblastoma , 2005, Journal of Neuro-Oncology.

[19]  D. Gutmann,et al.  Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. , 2005, Cancer research.

[20]  P. Casey,et al.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. , 2004, Journal of molecular biology.

[21]  F. Tamanoi,et al.  A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Kyriakis,et al.  A Novel Role for Mixed Lineage Kinase 3 (MLK3) in B-Raf Activation and Cell proliferation , 2004, Cell cycle.

[23]  E. Pérez-Nadales,et al.  The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation , 2004, The EMBO journal.

[24]  W. R. Bishop,et al.  Farnesyltransferase inhibitors as anticancer agents: critical crossroads. , 2004, Current opinion in drug discovery & development.

[25]  J. Sebolt-Leopold.  MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. , 2004, Current pharmaceutical design.

[26]  I. M. Bell.  Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? , 2004, Journal of medicinal chemistry.

[27]  D. Gutmann,et al.  Recent advances in neurofibromatosis type 1 , 2004, Current opinion in neurology.

[28]  D. Spandau,et al.  Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells. , 2004, The American journal of pathology.

[29]  A. Cox,et al.  Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells , 2004, Oncogene.

[30]  J. Baell,et al.  The Tyr-Kinase Inhibitor AG879, that Blocks the ETK-PAK1 Interaction, Suppresses the RAS-induced PAK1 Activation and Malignant Transformation , 2004, Cancer biology & therapy.

[31]  David A. Williams,et al.  Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells , 2003 .

[32]  D. Viskochil.  It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. , 2003, The Journal of clinical investigation.

[33]  R. Mattingly,et al.  Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways. , 2003, Cellular signalling.

[34]  M. Pierotti,et al.  p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  W. Su,et al.  Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression , 2003, Glia.

[36]  J. Eccleston,et al.  The mechanism of Ras GTPase activation by neurofibromin. , 2003, Biochemistry.

[37]  R. Deschenes,et al.  Identification of a Ras Palmitoyltransferase in Saccharomyces cerevisiae * , 2002, The Journal of Biological Chemistry.

[38]  Linyi Chen,et al.  The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase , 2002, The Journal of cell biology.

[39]  R. Gibbs,et al.  Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase , 2002, Journal of Pharmacology and Experimental Therapeutics.

[40]  S. Velasco-Miguel,et al.  Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. , 2002, Cancer research.

[41]  R. Zimmerman,et al.  Plexiform neurofibromas in NF1: toward biologic-based therapy. , 2002, Neurology.

[42]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[43]  Yinghua Zhu,et al.  Neurofibromin regulates G protein–stimulated adenylyl cyclase activity , 2002, Nature Neuroscience.

[44]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[45]  A. Adjei,et al.  Ras signaling pathway proteins as therapeutic targets. , 2001, Current pharmaceutical design.

[46]  R. Gibbs,et al.  Synthesis and evaluation of GGPP geometric isomers: divergent substrate specificities of FTase and GGTase I. , 2001, Bioorganic & medicinal chemistry letters.

[47]  L. Lim,et al.  Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. , 2001, Cancer journal.

[48]  G. Bollag,et al.  Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1−/− Cells* , 2001, The Journal of Biological Chemistry.

[49]  T. Roberts,et al.  Schwann Cell Proliferative Responses to cAMP andNf1 Are Mediated by Cyclin D1 , 2001, The Journal of Neuroscience.

[50]  D. Gutmann,et al.  Loss of Neurofibromin Is Associated with Activation of RAS/MAPK and PI3‐K/AKT Signaling in a Neurofibromatosis 1 Astrocytoma , 2000, Journal of neuropathology and experimental neurology.

[51]  L. Parada.  Neurofibromatosis type 1. , 2000, Biochimica et biophysica acta.

[52]  G. Benvenuto,et al.  Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. , 2000, The Journal of clinical investigation.

[53]  David A. Williams,et al.  Genetic and Biochemical Evidence That Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo , 2000, The Journal of experimental medicine.

[54]  J. Downward,et al.  Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma. , 1999, European journal of biochemistry.

[55]  T. Jacks,et al.  In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. , 1999, Blood.

[56]  K. Shannon,et al.  Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, American journal of medical genetics.

[57]  A. Guha,et al.  Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. , 1999, Surgical neurology.

[58]  P. Casey,et al.  Enzymology and biology of CaaX protein prenylation. , 1999, Recent progress in hormone research.

[59]  J. Schlegel,et al.  Expression of the ERBB2/neu and neurofibromatosis type 1 gene products in reactive and neoplastic schwann cell proliferation. , 1998, International journal of oncology.

[60]  A. Wittinghofer,et al.  Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. , 1998, Human molecular genetics.

[61]  J. Rutkowski,et al.  A role for Pak protein kinases in Schwann cell transformation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  N. Ratner,et al.  Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase , 1997, Molecular and cellular biology.

[63]  B. Seizinger,et al.  Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. , 1995, Cancer research.

[64]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[65]  S. Pulst,et al.  Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. , 1994, Developmental biology.

[66]  M. Boguski,et al.  Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules , 1993, Somatic cell and molecular genetics.

[67]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[68]  D. Lowy,et al.  Identification and characterization of the neurofibromatosis type 1 protein product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[69]  C. Marshall.  The ras oncogenes , 1988, Journal of Cell Science.